Schedule of Warrants Outstanding (Details) - $ / shares |
3 Months Ended | |||
|---|---|---|---|---|
Mar. 31, 2026 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Number Outstanding and Exercisable | 22,392,004 | 22,392,004 | 22,392,004 | |
| Weighted Average Remaining Contractual Life (years) | 1 year 29 days | |||
| Weighted Average Exercise price | $ 0.1963 | $ 0.1963 | $ 0.1963 | |
| Minimum [Member] | ||||
| Exercise Price | 0.1495 | |||
| Maximum [Member] | ||||
| Exercise Price | $ 0.2000 |
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|